Serotonergic anti-obesity agents: Past experience and future prospects

Drugs

Volumn 71, Issue 17, 2011, Pages 2247-2255

  Halford, Jason C G ^a   Boyland, Emma J ^a   Lawton, Clare L ^b   Blundell, John E ^b   Harrold, Joanne A ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Dexfenfluramine; Fenfluramine; Lorcaserin; Obesity; Sibutramine; Tesofensine

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; AGOUTI RELATED PROTEIN; ALPHA INTERMEDIN; AMFEBUTAMONE; ANTIOBESITY AGENT; DEXFENFLURAMINE; FENFLURAMINE; LORCASERIN; MELANOCORTIN; MELANOCORTIN 4 RECEPTOR; PHENTERMINE; PLACEBO; SEROTONIN; SEROTONIN 1B RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN AGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; TESOFENSINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; ZONISAMIDE;

ANGER; APPETITE; ARTICLE; BLOOD PRESSURE; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CONFUSION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENERGY BALANCE; ENERGY EXPENDITURE; FEEDING BEHAVIOR; HEART RATE; HOSTILITY; HUMAN; HUNGER; MENTAL DISEASE; MOOD DISORDER; NONHUMAN; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSYCHOPHARMACOLOGY; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SATIETY; SEROTONINERGIC SYSTEM; SIDE EFFECT; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

ANIMALS; BENZAZEPINES; BICYCLO COMPOUNDS, HETEROCYCLIC; HUMANS; OBESITY; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SEROTONIN AGENTS; SEROTONIN UPTAKE INHIBITORS;

RODENTIA;

EID: 81155154245     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11596680-000000000-00000     Document Type: Article

References (91)

1. National Institute for Health and Clinical Excellence. Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children. London: NI CE, 2006 Dec [online]. Available from URL: http://guidance.nice.org.uk/CG43 [Accessed 2011 Oct 14]
2. Hall KD, Sack G, Chandramohan D, et al. Quantification of the effect of energy imbalance on body weight. Lancet 2011; 378: 836-7
3. Pasman WJ, Saris WH, Westerterp-Plantenga MS. Predictors of weight maintenance. Obes Res 2006; 7: 43-50
4. Keys A, Brozek J, Henschel A, et al. The biology of human starvation. Vol. 1 & 2. St. Paul (MN): University of Minnesota Press, 1950
5. Blundell JE, Levin F, King NA, et al. Over-consumption and obesity: peptides and susceptibility to weight gain. Regul Pept 2008; 149: 32-8
6. Gautier JF, Chen KW, Salbe D, et al. Differential brain responses to satiation in obese and lean men. Diabetes 2000; 49: 838-46
7. Geliebter A, Yahav EK, Gluck ME, et al. Gastric capacity, test meal intake, and appetitive hormones in binge eating disorder. Physiol Behav 2004; 81: 735-40 (Pubitemid 38845040)
8. Meyer JE, Pudel V. Experimental studies on food-intake in obese and normal weight subjects. J Psychosom Res 1972; 16: 305-8
9. Spiegel TA, Wadden TA, Foster GD. Objective measurement of eating rate during behavioral treatment of obesity. Behav Ther 1991; 22: 61-7
10. Barkeling B, Ekman S, Rö ssner S. Eating behaviour in obese and normal weight 11-year-old children. Int J Obes 1992; 16: 335-60
11. Laessle RG, Lehrke S, Dü ckers S. Laboratory eating behavior in obesity. Appetite 2007; 49: 399-404 (Pubitemid 47374887)
12. Otsuka R, Tamakoshi K, Yatsuya H, et al. Eating fast leads to obesity: findings based on self-administered questionnaires among middle-aged Japanese men and women. J Epidemiol 2006; 16: 117-24 (Pubitemid 43796772)
13. Maruyama K, Sato S, Ohira T, et al. The joint impact on being overweight of self reported behaviours of eating quickly and eating until full: cross sectional survey. BMJ 2008; 337: a2002
14. Llewellyn CH, van Jaarsveld CH, Boniface D, et al. Eating rate is a heritable phenotype related to weight in children. Am J Clin Nutr 2008; 88: 1560-6
15. Mars M, de Graaf C, de Groot CP, et al. Fasting leptin and appetite responses induced by a 4-day 65%-energyrestricted diet. Int J Obes 2006; 30: 122-8 (Pubitemid 41790787)
16. Warren C, Cooper PJ. Psychological effects of dieting. Br J Clin Psychol 1988; 27: 269-70
17. Polivy J. Psychological consequences of food restriction. J Am Diet Assoc 1996; 96 (6): 589-92 (Pubitemid 126657059)
18. Hill AJ. The psychology of food craving. Proc Nutr Soc 2007; 66: 277-85
19. Karlsson J, Persson LO, Sjö ström L, et al. Psychometric properties and factor structure of the three-factor eating questionnaire (TFEQ) in obese men and women, results from the Swedish obese subjects (SOS) study. Int J Obes 2000; 24: 1715-25
20. Barkeling B, King NA, Nä slund E, et al. Characterization of obese individuals who claim to detect no relationship between their eating pattern and sensations of hunger or fullness. Int J Obes 2007; 31: 435-9
21. Provencher V, Drapeau V, Tremblay A, et al. Eating behaviours and indexes of body composition in men and women from the Quebéc family study. Obes Res 2003; 11: 783-92 (Pubitemid 41151605)
22. Dykes J, Brunner EJ, Martikeainene PT, et al. Socioeconomic gradient in body size and oboist among women: the role of dietary restraint, disinhibition and hunger in the Whitehall II study. Int J Obes 2004; 28: 262-8 (Pubitemid 38223508)
23. Lawson OJ, Williamson DA, Champagne CM, et al. The association of body weight, dietary intake, and energy expenditure with dietary restraint and disinhibition. Obes Res 1995; 3: 153-61
24. Williamson DA, Lawson OJ, Brookes ER, et al. Association of body mass with dietary restraint and disinhibition. Appetite 1995; 25: 31-41
25. Hays NP, Bathalon CP, McCrory MA, et al. Eating behaviour correlates of adult weight gain and obesity in healthy women aged 55-65 y. Am J Clin Nutr 2002; 75: 476-48
26. Bellisle F, Clement K, La Barzic M, et al. The eating inventory and body adiposity from leanness to massive obesity: a study of 2509 adults. Obes Res 2004; 12: 2023-30
27. Borg P, Fogelholm M, Kukkonen-Harjula K. Food selection and eating behaviour during weight maintenance intervention and 2-y follow-up in obese men. Int J Obes 2004; 28: 1548-54 (Pubitemid 39564332)
28. Stunkard A, Kaplan D. Eating in public places: a review of reports of the direct observation of eating behavior. Int J Obes 1977; 1: 89-101
29. Blundell JE, Stubbs RJ, Golding C, et al. Resistance and susceptibility to weight gain: individual variability in response to a high fat diet. Physiol Behav 2005; 86: 614-22 (Pubitemid 41728979)
30. Halford J CG, Harrold JA, Boyland EJ, et al. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 2007; 67 (1): 27-55 (Pubitemid 46105086)
31. Heisler LK, Cowley MA, Tecott LH, et al. Activation of central melanocortin pathways by fenfluramine. Science 2002; 297: 609-11 (Pubitemid 34815346)
32. Heisler LK, Cowley MA, Kishi T, et al. Central serotonin and melanocortin pathways regulating energy homeostasis. Ann N Y Acad Sci 2003; 994: 169-74 (Pubitemid 36793864)
33. Heisler LK, Jobst EE, Sutton GM, et al. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron 2006; 51: 239-49 (Pubitemid 44063615)
34. Halford J CG, Blundell JE. Separate systems for serotonin and leptin in appetite control. Ann Med 2000; 32: 222-32 (Pubitemid 30237567)
35. Blundell JE. Is there a role for serotonin (5-hydroxytryptamine) in feeding? Int J Obes 1977; 1 (1): 15-42
36. Blundell JE, Latham CJ. Pharmacological manipulation of feeding behaviour: possible influences of serotonin and dopamine on food intake. In: Garattini S, Samanin R, editors. Central mechanisms of anorectic drugs. New York: Raven Press, 1978: 83-109
37. Blundell JE, Latham CJ. Characteristic adjustments to the structure of feeding behaviour following pharmacological treatments: effects of amphetamine and fenfluramine and the antagonism by pimozide and metergoline. Pharmacol Biochem Behav 1980; 12: 717-22 (Pubitemid 10045717)
38. Halford J CG, Wanninayake S CD, Blundell JE. Behavioural satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behav 1998; 61: 159-68 (Pubitemid 28458908)
39. Clifton PG, Barnfield A MC, Philcox L. A behavioural profile of fluoxetine-induced anorexia. Psychopharmacology (Berl) 1989; 97 (1): 89-95
40. Simansky KJ, Viadya AH. Behavioural mechanisms for the anorectic actions of the serotonin (5-HT) uptake inhibitor sertraline in rats: comparison with directly acting agonists. Brain Res Bull 1990; 25: 953-60
41. Halford J CG, Blundell JE. 5-Hydroxytryptaminergic drugs compared on the behavioural sequence associated with satiety [abstract]. Br J Pharmacol 1993; 100: 95
42. Kitchener SJ, Dourish CT. An examination of the behavioural specificity of hypophagia induced by 5-HT1B, 5-HT1C and 5-HT2 receptor agonists using the post-prandial sequence in rats. Psychopharmacology (Berl) 1994; 113 (3-4): 368-77
43. Halford J CG, Blundell JE. Metergoline antagonizes fluoxetine induced suppression of food intake but not changes in the behavioural satiety sequence. Pharmacol Biochem Behav 1996; 54: 745-51 (Pubitemid 26258659)
44. Halford J CG, Blundell JE. The 5-HT1B receptor agonist CP-94, 253 reduces food intake and preserves the behavioural satiety sequence. Physiol Behav 1996; 60: 933-9 (Pubitemid 26284299)
45. Lee MD, Simansky KJ. CP-94, 253: a selective serotonin1B (5-HT1B) agonist that promotes satiety. Psychopharmacology (Berl) 1997; 131 (3): 264-70 (Pubitemid 27283588)
46. Lee MD, Kennett GA, Dourish CT, et al. 5-HT1B receptors modulate components of satiety in the rat: behavioural and pharmacological analyses of the selective serotonin1B agonist CP-94, 253. Psychopharmacology (Berl) 2002; 164 (1): 49-60 (Pubitemid 35203842)
47. Hewitt KN, Lee MD, Dourish CT, et al. Serotonin 2C receptor agonists and the behavioural satiety sequence in mice. Pharmacol Biochem Behav 2002; 71: 691-700 (Pubitemid 34219219)
48. Kennett GA, Curzon G. Evidence that the hypophagia induced by mCPP and TFMPP requires 5-HT1C and 5-HT1B receptors; hypophagia induced by RU-24969 only requires 5-HT1B receptors. Psychopharmacology (Berl) 1988; 96: 93-100
49. Kennett GA, Curzon G. Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors. Br J Pharmacol 1988; 94: 137-47
50. Kennett GA, Curzon G. Potencies of antagonists indicate that 5-HT1C receptors mediate 1-3(chlorophenyl)-piperazine-induced hypophagia. Br J Pharmacol 1991; 10: 2016-20
51. Jackson HC, Bearham MC, Hutchins LJ, et al. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol 1997; 121: 1613-8 (Pubitemid 27343387)
52. Vickers SP, Dourish CT, Kennett GA. Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors. Neuropharmacology 2001; 41: 200-9 (Pubitemid 32728091)
53. Higgs S, Cooper AJ, Barnes NM. Reversal of sibutramineinduced anorexia with a selective 5-HT2C receptor antagonist. Psychopharmacology (Berl) 2011; 214 (4): 941-7
54. Tecott LH, Sun LM, Akanna SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 1995; 374: 542-6
55. NonogakiK, Abdullah L, Goulding EH, et al. Hyperactivity and reduced energy cost of physical activity in serotonin 5-HT2C receptor mutant mice. Diabetes 2003; 52: 315-20 (Pubitemid 36173184)
56. Bouwknecht JA, van der Guten J, Hijsenm TH, et al. Male and female 5-HT1B receptor knockout mice have higher body weights than wild types. Physiol Behav 2001; 74: 507-16 (Pubitemid 34076596)
57. Rogers PJ, Blundell JE. Effect of anorexic drugs on food intake and the micro-structure of eating in human subjects. Psychopharmacology (Berl) 1979; 66 (2): 159-65 (Pubitemid 10180146)
58. Goodall E, Silverstone T. Differential effect of dfenfluramine and metergoline on food intake in human subjects. Appetite 1988; 11: 215-88
59. McGuirk J, Silverstone T. The effect of 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects. Int J Obes 1990; 14: 361-72 (Pubitemid 20212177)
60. Hansen DL, Toubro S, Stock MJ, et al. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 1998; 68: 1180-6 (Pubitemid 28550946)
61. Chapelot D, Mamonier C, Thomas F, et al. Modalities of the food intake-reducing effect of sibutramine in humans. Physiol Behav 2000; 68: 299-308 (Pubitemid 30100696)
62. Blundell JE, Hill AJ. Sensitivity of the appetite control system in obese subjects to nutritional and serotoninergic challenges. Int J Obes 1990; 14: 219-33 (Pubitemid 20150407)
63. Drent ML, Zelissen P MJ, Kopperchaar H PF, et al. The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks. Int J Obes 1995; 19: 299-304
64. Lawton CL, Wales JK, Hill AJ, et al. Serotoninergic manipulation, meal-induced satiety and eating patterns. Obes Res 1995; 3: 345-56
65. Pijl H, Koppeschaar H PF, Willekens F LA, et al. Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. Int J Obes 1991; 15: 237-42
66. Rolls BJ, Shide DJ, Thorward ML, et al. Sibutramine reduces food intake in non-dieting women with obesity. Obes Res 1998; 6: 1-11 (Pubitemid 128679638)
67. Halford J CG, Boyland EJ, Cooper SJ, et al. The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women. J Psychopharmacol 2010; 24: 99-109
68. Walsh AE, Smith KA, OldmanAD.M-Chlorophenylpiperazine decreases food intake in a test meal. Psychopharmacol 1994; 116: 120-2 (Pubitemid 24279609)
69. Cowen PJ, Sargent PA, Williams C, et al. Hypophagic, endocrine and subjective responses to m-chlorophenylpiperazine in healthy men and women. Hum Psychopharmacol 1995; 10: 385-91
70. Sargent PA, Sharpley AL, Williams C, et al. 5-HT2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacol 1997; 133: 309-12 (Pubitemid 27445666)
71. Haddock CK, Poston W SC, Dill PL, et al. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes 2002; 26: 262-73 (Pubitemid 34151206)
72. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Int Med 2004; 164: 994-1003 (Pubitemid 38581520)
73. Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for overweight and obesity: a systematic review and metaanalysis of randomized controlled trials. Int J Obes 2003; 27: 1437-46 (Pubitemid 38019154)
74. Abeniam L, Moride Y, Brenot F, et al. Appetite suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609-16 (Pubitemid 26277950)
75. James W PT, Caterson ID, Coutinho W, et al. Effects of sibutramine on cardiovascular outcomes in overweight and obesity subjects. N Engl J Med 2010; 363: 905-17
76. Astrup A. Drug management of obesity: efficacy versus safety. N Engl J Med 2010; 363: 288-90
77. Smith SR, Prosser WA, Donahue DF, et al. Lorcaserin (APD356), a selective 5-HT2C agonist, reducing body weight in obese men and women. Obes 2009; 17: 494-500
78. Bjenning C, Williams J, Whelan K, et al. Chronic oral administration of APD356 significantly reduces body weight and fat mass in obesity-prone (DIO) male and female rats [abstract]. Int J Obes 2004; 28 (1 Suppl.): 214s
79. Smith S, Anderson J, Frank A, et al. The effects of APD356, a selective 5-HT2C agonist, on weight loss in a 4 week study in healthy obese patients [abstract]. Obes Res 2005; 13 Suppl.: 101-OR
80. Martin CK, Redman LM, Zhang J, et al. Lorcaserin, a 5-HT2C receptor agonist, reduced body weight by decreasing energy intake within influencing energy expenditure. J Clin Endocrinol Metab 2011; 96: 837-45
81. Smith SR, Wiessman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial for lorcaserin for weight management. N Engl J Med 2010; 363: 245-56
82. Halford JCG. Obesity: lorcaserin-not a new weapon in the battle with appetite. Nat Rev Endocrinol 2010; 6: 663-4
83. Doggrell SA. Tesofensine: a novel potent weight loss medicine. Exp Opin Investig Drugs 2009; 18: 1043-6
84. Bello NT, Zahner MR. Tesofensine, amonoanime reuptake inhibitor for the treatment of obesity. Curr Opin Investig Drugs 2009; 10: 1105-16
85. Lehr T, Staab A, Tillmann C, et al. Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach. Br J Pharmacol 2008; 153: 164-74
86. BerridgeKC. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacol 2007; 191: 391-431 (Pubitemid 46355895)
87. Axel A MD, Mikkelsen JD, Hansen HH. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology 2010; 35 (7): 1464-76
88. Hansen HH, Hansen G, Tang-Christensen M, et al. The novel triple monoamine reuptake inhibitor tesofensine induced sustained weight loss and improved glycaemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol 2010; 636: 88-95
89. Sjö din A, Gasteyger C, Nielen A-LH, et al. The effect of the tripe monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese mean. Int J Obesity 2010; 34: 1634-43
90. Astrup A, Madshad S, Breum L, et al. Effect of tesofensine on body weight loss, body composition and quality of life in obese patients: a randomised, double-blind, placebocontrolled trial. Lancet 2008; 372: 1906-13
91. Schoedel KA, Meier D, Chekroborty B. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clin Pharmacol Ther 2010; 88 (1): 69-78